ProCE Banner Activity

Phase II Interim Analysis of FcRn Inhibitor Rozanolixizumab in Adult Patients With Primary Immune Thrombocytopenia

Slideset Download
Conference Coverage
Most treatment-emergent adverse events were mild to moderate in adult ITP patients receiving 4 or 7 mg/kg of rozanolixizumab subcutaneously.

Released: December 20, 2017

Expiration: December 19, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Novartis Pharmaceuticals Corporation